AACR Congress 2022: A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA)

NG-641 is a novel tumor-selective adenoviral vector that expresses four potent immuno-stimulatory transgenes: a fibroblast activation protein-directed bi-specific T-cell activator antibody, CXCL9, CXCL10 and FNα2.

  • Therapeutic approaches to re-programme immunosuppressive TMEs may improve responsiveness to immunotherapy
  • NG-641 combines systemic delivery with localized activity at both primary and metastatic tumors

The phase 1a/1b NEBULA study will assess NG-641 in combination with nivolumab in patients with advanced/metastatic epithelial tumors

Safety and tolerability will be assessed using a BOIN dose-escalation design

Pharmacodynamic outcomes, including immune/inflammatory responses and cytokine production will be assessed

View AACR  2022 NEBULA Poster Here